Aegerion Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

DALLAS--(BUSINESS WIRE)--Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Aegerion Pharmaceuticals, Inc. (“Aegerion” or “Company”) (NasdaqGS: AEGR) and several officers and directors for acts taken during the period of March 15, 2012 to January 9, 2014 (the “Class Period”).

Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Aegerion. If you are an affected Aegerion shareholder and want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, [phone], or via email at [e-mail], or Zach Groover at Powers Taylor LLP, toll free [phone], or via e-mail at [e-mail]. There is no cost or fee to you.

In the complaint, the defendants are alleged to have violated certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges that defendants misrepresented and/or failed to disclose that: a) Aegerion marketed its drugs in violation of the FDCA; b) due to this violation, Aegerion faced heightened regulatory scrutiny by the FDA and other governmental bodies; and c) as a result of the above, Aegerion’s statements were materially false and misleading at all relevant times. According to the complaint, Aegerion’s stock price dropped dramatically after the true facts were revealed.

The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.